Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 17, 2017 (9 years ago)

Nystatin Oral Suspension

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: Presence of an impurity peak that exceeds approved specification.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Nystatin Oral Suspension, USP, 100,000 units/mL, packaged in a) 2 fl.oz. (60mL) bottles (NDC 66689-008-02), and 500,000 units/5mL individual unit dose cup (NDC 66689-037-01) packaged in b) 50 count unit dose cups/case (NDC 66689-037-50) and c) 100 count unit dose cups/case (NDC 66689-037-99) Rx only, Manufactured by: VistaPharm, Largo, FL 33771.

Affected NDCs 66689-0008-02 66689-0037-01 66689-0037-50 66689-0037-99

Compare with the code on your package — it is the most precise check available.

Drug: Nystatin

Recalling firm
VistaPharm, Inc.
NDC code
66689-008-02
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0869-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nystatin recalls

See all
Class II · Moderate risk

Nystatin Cream USP

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Ongoing Wrong potency / content Padagis US LLC NDC 45802-059-35 D-0677-2026
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024

Other recalls by VistaPharm, Inc.

All 2017 recalls